Novartis Says Chair Contradicted Admissions In FCA Deal
By Adam Lidgett · March 26, 2021, 8:08 PM EDT
Novartis said its chairman incorrectly contradicted the company's admissions that it made as part of a $678 million deal with the federal government to settle claims it flouted the False Claims...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login